文档介绍：Acute Lymphoblastic Leukemia in Adults
Session Chair: Richard A. Larson, MD
Speakers: Oliver G. Ottmann, MD; Daniel J. DeAngelo, MD, PhD; and Richard A. Larson, MD
Treatment of Philadelphia Chromosome–
Positive Acute Lymphoblastic Leukemia
Oliver G. Ottmann and Barbara Wassmann
Philadelphia chromosome positive (Ph+) acute lympho- mesylate and other tyrosine kinase inhibitors and
blastic leukemia (ALL) includes at least one-quarter of small molecules that affect the BCR/ABL signaling
all adults with ALL. Until recently, conventional pathways may be changing the treatment paradigm
chemotherapy programs that have been effective in and the prognosis for these patients. The results from
other precursor B-cell ALL cases have been unable to clinical trials using imatinib in the frontline setting and
cure patients with this diagnosis. Allogeneic stem cell in relapsed patients as well as preliminary experience
transplantation early in first remission has been the treating imatinib-resistant Ph+ ALL will be described.
mended therapy. The availability of imatinib
Clinical Features of Ph+ ALL gens, and frequent coexpression of myeloid markers, .,
The Philadelphia chromosome (Ph), the result of a recipro- CD13 and CD33. Patients have an increased risk of devel-
cal translocation fusing the abl proto-oncogene from chro- oping meningeal leukemia during the course of trea